Bayer AG - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 202 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Bayer AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Bayer AG - Product Pipeline Review - 2014', provides an overview of the Bayer AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bayer AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bayer AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bayer AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Bayer AG's pipeline products

Reasons to buy

- Evaluate Bayer AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bayer AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bayer AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bayer AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bayer AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bayer AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Bayer AG Snapshot 6
Bayer AG Overview 6
Key Information 6
Key Facts 6
Bayer AG - Research and Development Overview 7
Key Therapeutic Areas 7
Bayer AG - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 18
Bayer AG - Pipeline Products Glance 20
Bayer AG - Late Stage Pipeline Products 20
Bayer AG - Clinical Stage Pipeline Products 24
Bayer AG - Early Stage Pipeline Products 28
Bayer AG - Unknown Stage Pipeline Products 30
Bayer AG - Drug Profiles 31
(gestodene + ethinyl estradiol) 31
aflibercept 33
regorafenib 36
riociguat 39
sorafenib tosylate 41
rivaroxaban 45
(diphenhydramine hydrochloride + naproxen sodium) 49
(nifedipine + candesartan cilexetil) 50
amikacin 51
BAY-818781 53
BAY-818973 54
BAY-949027 56
ciprofloxacin 57
mapracorat 60
radium Ra 223 dichloride 62
tedizolid phosphate 65
BAY-1002670 67
BAY-1021189 68
BAY-1067197 69
BAY-858501 70
copanlisib 71
finerenone 74
molidustat 75
refametinib 76
sagopilone 79
BAY-1000394 81
Autologous Recombinant Idiotypic Vaccine 83
BAY-1026153 84
BAY-1082439 85
BAY-1125976 86
BAY-1129980 87
BAY-1143572 88
BAY-1163877 89
BAY-1179470 90
BAY-868050 91
BAY-949343 92
BAY-1001931 94
BAY-1024767 95
BAY-606583 96
Bay-846 97
BR-4628 98
BR-5489 99
HER-2 Payload 100
Monoclonal Antibodies for Cancer 101
PDGFR-Beta Payload 102
Small Molecule to Inhibit Kinase for Cancer 103
ZK-191784 104
ZK-216348 106
Small Molecule to Inhibit Epigenetic Target for Cancer 107
Thorium-227 Avibody Conjugate 108
Thorium-Anti CD22 Monoclonal Antibody 109
Drugs Targeting Tumor Specific Gene Mutations for Cancer 110
Immunotherapy for Cancer 111
Bayer AG - Pipeline Analysis 112
Bayer AG - Pipeline Products by Target 112
Bayer AG - Pipeline Products by Route of Administration 116
Bayer AG - Pipeline Products by Molecule Type 117
Bayer AG - Pipeline Products by Mechanism of Action 118
Bayer AG - Recent Pipeline Updates 123
Bayer AG - Dormant Projects 180
Bayer AG - Discontinued Pipeline Products 183
Discontinued Pipeline Product Profiles 183
Bayer AG - Company Statement 185
Bayer AG - Locations And Subsidiaries 187
Head Office 187
Other Locations & Subsidiaries 187
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 198
Disclaimer 198

List of Tables
Bayer AG, Key Information 10
Bayer AG, Key Facts 10
Bayer AG - Pipeline by Indication, 2014 13
Bayer AG - Pipeline by Stage of Development, 2014 17
Bayer AG - Monotherapy Products in Pipeline, 2014 18
Bayer AG - Combination Treatment Modalities in Pipeline, 2014 19
Bayer AG - Partnered Products in Pipeline, 2014 20
Bayer AG - Partnered Products/ Combination Treatment Modalities, 2014 21
Bayer AG - Out-Licensed Products in Pipeline, 2014 22
Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 23
Bayer AG - Pre-Registration, 2014 24
Bayer AG - Filing rejected/Withdrawn, 2014 25
Bayer AG - Phase III, 2014 26
Bayer AG - Phase II, 2014 28
Bayer AG - Phase I, 2014 30
Bayer AG - Preclinical, 2014 32
Bayer AG - Discovery, 2014 33
Bayer AG - Unknown, 2014 34
Bayer AG - Pipeline by Target, 2014 116
Bayer AG - Pipeline by Route of Administration, 2014 120
Bayer AG - Pipeline by Molecule Type, 2014 121
Bayer AG - Pipeline Products by Mechanism of Action, 2014 123
Bayer AG - Recent Pipeline Updates, 2014 127
Bayer AG - Dormant Developmental Projects,2014 184
Bayer AG - Discontinued Pipeline Products, 2014 187
Bayer AG, Subsidiaries 191